Preferred Label : Autologous Anti-NKG2DL/Anti-CLDN18.2 Bispecific CAR-T Cells KD-496;
NCIt synonyms : Autologous Anti-NKG2DL/CLDN18.2 Bispecific CAR-T Cells KD-496; Tan-CAR-T Cells KD-496; Autologous Anti-NKG2DL/CLDN18.2 Bispecific CAR T-cells KD-496; Autologous Anti-NKG2DL/CLDN18.2 Bispecific CAR T Cells KD-496;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a tandem chimeric antigen receptor (CAR) targeting the tumor-associated antigens (TAAs)
natural-killer group 2, member D ligands (NKG2DLs) and Claudin18.2 (CLDN18.2; A2 isoform
of claudin-18), with potential immunostimulating and antineoplastic activities. Upon
administration, autologous anti-NKG2DL/anti-CLDN18.2 bispecific CAR-T cells KD-496
specifically and simultaneously recognize and induce selective toxicity in tumor cells
expressing NKG2DLs and CLDN18.2. Ligands for NKG2D, such as MHC class I chain-related
protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid
early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer
cell types, but are not expressed on most normal, healthy cells. CLDN18.2, a tight
junction protein, is expressed on a variety of tumor cells, but its expression in
healthy tissues is strictly confined to short-lived differentiated epithelial cells
of the gastric mucosa.;
Molecule name : KD-496; KD 496;
NCI Metathesaurus CUI : CL1912838;
Origin ID : C192807;
UMLS CUI : C5785430;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
